Home › Trials › NCT05930275

Assessing the effectiveness of Upadacitinib for Crohn's Disease in real-world settings

A Multi-country, Prospective, Post-marketing Study of UPadacitinib Evaluating Speed of Onset and Durability of Effectiveness for Patients With Moderate to Severe Crohn's Disease for 3 Years in Real-world Clinical Practice (UPlift)

Observational AbbVie · NCT05930275

This study is testing how well Upadacitinib works and how safe it is for adults with moderate to severe Crohn's Disease in everyday medical settings.

Quick facts

Study typeObservational
Enrollment1200 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsupadacitinib
Locations177 sites (Blacktown, New South Wales and 176 other locations)
Trial IDNCT05930275 on ClinicalTrials.gov

What this trial studies

This observational study evaluates the safety and effectiveness of Upadacitinib in adults with moderate to severe Crohn's Disease (CD) in real-world clinical practice. Approximately 1200 participants will be enrolled across 230 sites globally, receiving Upadacitinib as prescribed by their physicians. The study will assess the speed of onset and durability of the drug's effectiveness over a follow-up period of up to 3 years, with minimal additional burden on participants. Visits may occur on-site or virtually, aligning with standard care practices.

Who should consider this trial

Good fit: Ideal candidates include adults diagnosed with moderate to severe Crohn's Disease who are initiating Upadacitinib treatment as part of their routine clinical care.

Not a fit: Patients with contraindications to Upadacitinib or those previously exposed to the drug in clinical trials may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness of Upadacitinib for managing Crohn's Disease.

How similar studies have performed: Other studies have shown positive outcomes with Upadacitinib for Crohn's Disease, indicating a promising approach in this observational context.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* A diagnosis of moderate-to-severe crohn's disease (CD).
* Participants initiating upadacitinib at the clinician's discretion as part of their routine clinical care; the decision to administer upadacitinib must be made prior to and independent of recruitment into the study.
* Participants prescribed upadacitinib in accordance with the approved local label.
* Able to understand and communicate with the investigator and comply with the requirements of the study.
* Willing to continue with study documentation after cessation of upadacitinib.
* Willing and able to participate in the collection of PRO data via a cloud-based application on their personal or provided mobile phone or website app.

Exclusion Criteria:

* Any contraindication to upadacitinib.
* Previously exposure to upadacitinib in a clinical trial.
* Currently participating in interventional research (not including non-interventional study, post-marketing observational study (PMOS) , or registry participation).
* Initiation of upadacitinib prior to enrollment.

Where this trial is running

Blacktown, New South Wales and 176 other locations

+127 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Crohn's DiseaseCrohn's diseaseCDUpadacitinib
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.